Characterization of CD3+, CD4-, CD8- clones expressing the putative T cell receptor gamma gene product. Analysis of the activation pathways leading to interleukin 2 production and triggering of the lytic machinery by unknown
BriefDefinitive Report
CHARACTERIZATION OF CD3+, CD4-, CD8- CLONES
EXPRESSING THE PUTATIVE T CELL RECEPTOR
,y GENE PRODUCT
Analysis ofthe Activation Pathways Leading to Interleukin 2
Production and Triggering of the Lytic Machinery
BY SILVANO FERRINI,* CRISTINA BOTTINO,$ ROBERTO BIASSONIß
ALESSANDRO POGGI,$ RAFICK P. SEKALY,1 LORENZO MORETTA,* AND
ALESSANDRO MORETTA*
From the *Istituto Nazionale per la Ricerca sul Cancro, 16132 Genova, Italy; the *Ludwig
Institutefor Cancer Research, Lausanne Branch, CH-1066 Epalinges, Switzerland ; and the
4National Institutes ofHealth, Bethesda, Maryland 20892
The surface molecules that serve as receptor for antigen/MHC recognition
are composed of a disulfide a/ß heterodimer noncovalently associated with CD3,
a multipolypeptide cell membrane complex (1, 2) . However, a minor cell subset
has recently been identified that does not express a/ß molecules in association
with CD3 (3) . In addition to the lack of reactivity with theWT31 mAb (specific
for a framework determinant of the a/ß heterodimer), these cellsdo not express
CD4 or CD8 differentiation antigens (3), which are expressed by distinct subsets
of conventional CD3' cells . A number of CD3+, WT31 - cells, including cell
lines, from immunodeficiency patients (4), clones derived from fetal blood (5),
or thymus (6), and a leukemia (7) were recently found to express C133-associated
molecules, different from a/ß molecules, which may represent the putative T
cell receptor (TCR)-y gene product . Thus far, little is known on the functional
activities of CD3', WT31- cells and on the surface molecules and mechanisms
for activating these lymphocytes to express their functional program(s) .
In this study, we analyzed four CD3+, WT31 - clones derived from CD3+, 2+,
4- , 8- normal peripheral blood populations . The expression of a major CD3-
associated 45 kD molecule, together with the detection ofy mRNA and the lack
of mature a and ß mRNA suggested that these clones may express the TCR-y
gene product. In addition, we show that, like CD3+ , WT31+ cells, signalling via
either CD3 or CD2 surface molecules activatedCD3', WT31 - clones to produce
lymphokines or to mediate cytolytic activity . Therefore, molecules that function
as surface receptors for activation in typical CD3' cells (equipped with an a/ß
TCR) can also activate in CD3+, 4-, 8- cells expressing the putative TCR-y gene
product .
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Materials and Methods
Isolationand CloningofCD3+, CD4-, CD8-Lymphocytes.
￿
Peripheral blood lymphocytes
from normal volunteers were isolated by Ficoll-Hypaque gradients and then separated
into E rosetting-positive and -negative populations. E-rosetting cells were then stained
with a mixture of anti-CD4 and anti-CD8 mAbs followed by treatment with rabbit
complement for 1 h at 37 ° C. Viable cells were cultured in limiting-dilution conditions in
the presence of autologous irradiated feeder cellsand a source of exogenous IL-2 derived
from spleen cells stimulated with PHA as described (8). Cell clones were screened directly
by FACS analysis for the presence of surface CD3 and the simultaneous lack of CD4 or
CD8 antigens. The mAbs used in these experiments were Leu-4 (anti-CD3) (Becton
Dickinson and Co., Basel, Switzerland), CD2-1, CD2-9, and MAR 206 (all directed to
CD2), B9.4 (anti-CD8), CK.79 (anti-CD4), and CK.248 (anti-T44) were isolated in our
laboratory as previously described (9). FACS analysis was also performed after staining
with the WT31 mAb directed to a framework of the a/ß T cell receptor. An additional
anti-T44 mAb (9.3) was provided by Dr. ,J. Hansen (Fred Hutchinson Cancer Research
Center, Seattle, WA).
Functional Analysis of T Cell Clones.
￿
Production of IL-2 from clones was assessed by
culturing 105 cloned cells/well in the presence of autologous irradiated feeder cells and
either one of the following stimuli: anti-CD3 mAb (10 F1 of culture supernatant), anti-
T44 mAb (10 gl of culture supernatant), PHA (1 % vol/vol) or a mixture of two anti-CD2
mAbs (CD2-9 + CD2-1) that were previously shown to be stimulatory on resting as well
as on activated T cells (9). After 24 h, culture supernatants were removed and each tested
in an indicator cell system consisting of the IL-2-responsive murine CTLL cell line as
described previously (10). The cytolytic activity of the clones was tested in a 4-h "Cr-
release assay in which 1 .5 x 104 cloned cells were used as effector cells against different
types of target cells: the NK-sensitive K562 cell line, the hybridoma producing anti-CD3
mAb and the two hybridoma producing two distinct stimulatory anti-CD2 mAb. All these
target cells were used at 5 x 10' cells/well for a final effector/target cell ratio of 3:1 .
Percent specific lysis was determined as previously described (8).
Immunoprecipitation.
￿
Cloned cells (5 x 106) were radioiodinated by the lactoperoxidase
technique and then intact cells were crosslinked by incubation in 600 JAI PBS (pH 8)
containing 25 ag dithiobis-succinimidyl propionate (DSP) for 45 min at room temperature
as previously described (2). Cells were then solubilized in buffer containing 1 % NP-40
and immunoprecipitated as described (11). After immunoprecipitation samples were
examined by SDS-PAGE under reducing conditions using 5% 2-ME, which cleaves both
disulfide bond between protein subunits and the chemical crosslinker.
Northern Analysis. RNA was extracted from frozen cell pellets by the guanidium
thiocyanate method and purified by centrifugation through a CsCl gradient. RNA was
size-fractionated by electrophoresis in a 15% agarose gel containing formaldehyde and
was transferred by capillary suction to a charged Nylon membrane (Gene-Screen Plus,
New England Nuclear, Boston, MA) in 1.5 M NaCl, 0.15 M sodium citrate. Hybridization
of the filters with "P-labeled DNA probes and the washing of the filters were performed
as described (12). Human Ta, Tß, and Ty cDNA probes (kindly provided by Dr. Tak
Mak, Ontario Cancer Institute, Toronto, Canada) have been previously described (13,
14).
Results and Discussion
Clones were derived by limiting dilution from E-rosetting cells from which
CD4+ and CD8 cells were removed by treatment with mAb + C depletion. Four
clones that expressed the CD2'}, 3', 4-, 8-, WT31 - surface phenotype were
further expanded in IL-2-containing media.
Surface labelling followed by crosslinking and immunoprecipitation with anti-
CD3 mAbs showed (Fig. 1) that, in all four clones, CD3-associated molecules
consisted of a major 45 kD band and a slightly lower band of ^"43 kD (underFERRINI ET AL . BRIEF DEFINITIVE REPORT
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FIGURE 1 .
￿
lmmunoprecipitation andSDS-PAGEanalysis ofthe CD3-
associated molecules expressed on CD3', WT31- clones. The four
CD3', WT31- clones (lanes B-E) and one CD3',WT31+ (lane A) were
labeled with `sst, intact cells were crosslinked with DSP, and immuno-
precipitated with anti-CD3mAb as described in Materialsand Methods .
Immunoprecipitates were analyzed using 11% acrylamide gels under
reducing conditions .
TABLE I
Cytolytic Activity ofCD3', WT31 - Clones
* CD3, CD2-1, CD2-9, and T44 refer to hybridomas producing mAb to these antigens. Anti-CD2 hybridoma were
used either alone or in combination. In the latter case only one of the two hybridomas was "Cr-labeled. In the
data reported for the combined use of CD2-1 + CD2-9, only the CD2-9 hybridoma was labeled ; no significant
changes were observed when the "Cr-labeled hybridoma was CD2-1 .
reducing conditions) . Similar CD3-associated molecules were also observed by
Moingeon et al . (5) in immunoprecipitates from a CD3', 8'}, WT31 - clone
derived from fetal lymphocytes . On the other hand, a CD3+, 4- , 8-, WT31-
clone derived from human thymus, expressed, together with a 44 kD molecule,
a heavier 62 kD molecule associated with CD3 (6). Different molecular masses
(55 and 40 kD) for CD3-associated molecules in CD3', WT31- cell lines, derived
from immunodeficiency patients, have been reported by Brenneret al . (4). These
authors first proposed that the 55 kD molecule may represent the putative
surface product of the TCR-'y genes . This possibility was also supported by the
observation that these cells expressed mRNA for the y chain, while mRNA for
a and ,8 chains were missing . We further investigated the presence ofmRNA for
different TCR chains in three clones . Northern blot analysis demonstrated that
mRNA for the y chain was expressed at high levels . In contrast, nomRNA could
be detected for the a chain, whereas a defective mRNA for the ,B chain (1 kb
instead of 1 .3 kb) was present (data not shown) . This finding, together with the
results of immunoprecipitation experiments, supports the notion that they gene
molecular product, rather than thea or ,8 chain were associated to CD3 molecules
in our clones .
Next, clones were characterized for their functional capabilities . As shown in
Table I, all four clones lysed the NK-sensitive K562 target cells, although with
different efficiencies . Because conventional CD3+, WT31 + CTLs and CD2+,
CD3- NK cells can be induced to lyse target cells after stimulation with mAbs
directed to the CD3/TCR molecular complex (15) or to CD2 molecules (16),
respectively, we investigated whether similar mechanisms of activation of the
lytic machinery were also functioning in CD3', 2+ , WT31 - cells. To this end,
we used as triggering targets hybridomas producing mAbs directed to CD3 or
CD2 molecules (15) . As shown in Table I, all the clones efficiently lysed the anti-
CD3 mAb-producing hybridoma . On the other hand, control hybridomas pro-
Clone
K562
Percent
CD3*
"Cr release from
CD2-1
labeled target
CD2-9
cells:
CD2-1 +
CD2-9 T44
A17 43 62 3 1 48 3
S5 57 43 5 6 67 7
S11 38 67 2 2 46 2
S12 20 61 2 1 39 4280
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TABLE II
IL-2 Production by CD3+, WT31 - Clones
* Clones A17, S5, S11, and S12 are CD3', WT3I - whereas R7 and R14 are two CD3", CD8', WT31' clones
showed for comparison. One of the CD8' clones produced IL-2, whereas the second did not.
* All the various stimuli were given in the presence of irradiated autologous feeder cells. The stimulatory
combination ofanti-CD2 mAb used was represented by CD2-1 + CD2-9 mAb, as previously described (12). IL-
2 production by the different clones was assessed as indicated in Materials and Methods.
ducing mAbs directed against a number of surface molecules, were not lysed
(not shown). In Table I, the hybridomaproducing anti-T44 mAb is shown, mAbs
to T44 molecules are known to mediate Tcell activation (11, 17). Interestingly
enough, all the clones studied (as well as the starting CD3+, 4-, 8-, WT31 - cell
population) neither expressed the T44 surface molecule nor lysed the anti-T44
producing hybridoma. Therefore, a putative alternative pathway of T cell
activation is missing in this T cell subset. Anti-CD2-secreting hybridomas as
triggering targets have been used to study whether induction ofcytolytic activity
could occur also via CD2 surface molecules. It is now well established that
appropriate combinations ofmAbs directed to distinct epitopes ofCD2 molecule
can trigger conventional T cells to express their functional program (9). There-
fore, we used a combination of hybridomas producing anti-CD2 mAbs which,
when used together, were shown to activate CD3+, WT31+ cells (9). Neither one
of the two anti-CD2 hybridomas was lysed when used alone, whereas efficient
killing occurred when they were used in combination (Table I).
We have shown that most CD3'}, 4-, 8- clones produced IL-2 and IFN-?'
following stimulation with PHA (18). As shown in Table 11, all of the clones
analyzed released IL-2 after PHA stimulation, moreover, efficient stimulation
could be achieved by using anti-CD3 mAbs or a suitable combination of anti-
CD2 mAbs. The release of IL-2 was comparable in magnitude to that of a
representative CD3+, WT31 + clone. Note also that only the latter clone was
responsive to stimulation with an anti-T44 mAb. Although not shown, all the
clones produced IFN-y as well. Our present data indicate that CD3+, 4-, 8-,
WT31 - cells display multiple functional capabilities that can be triggered via the
CD3/TCR complex, as well as via CD2 molecules. Thus, these cells appear to
use for cell activation surface structures similar to those used by CD3+, WT31 +
T lymphocytes. The question remains as to how antigen recognition via y chain
molecules occurs. The lack of CD4 and CD8 surface antigen may suggest that
TCR -y-positive cells bind target cells without the need for recognition of MHC
molecules.
The differences in the molecular mass reported by different groups for the
CD3-associated molecules in WT31- cells may reflect (a) different techniques
used for immunoprecipitation and/or crosslinking, (b) a different degree of
Clone* Surface phenotype
['H]TdR
Medium
uptake (cpm x
PHA
10-') by cells
Anti-CD3
cultured in
Anti-CD2
presence of.*
Anti-T44
A17 CD3*, 4-, 8-, WT31 - 0.3 24.8 28.3 26.1 0.4
S5 CD3', 4-, 8-, WT31 - 0.7 19.0 28.9 24.2 1 .4
S11 CD3', 4-, 8-, WT31 - 1 .2 41 .7 66.2 72.3 1.3
S12 CD3', 4-,8-, WT31 - 1 .4 22.9 17 .4 18.3 ND
R7 CD3', 4-, 8', WT31' 0.7 0.8 0.7 ND 0.9
R14 CD3', 4-, 8', WT31' 0.8 28.4 14.2 11.4 15.1FERRINI ET AL.
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glycosylation in cells derived from various CD3', WT31 - cell populations (in-
cluding thymus, fetal tissue, cells from immunodeficiency patients, and leukemic
cells). Note however that no major differences in molecular mass could be
detected in different clones all derived from peripheral blood of healthy donors.
It is also of note that CD3-associated molecules precipitated from the same clones
under conditions that preserve the TCR-CD3 association (7) showed a molecular
mass of 80 kD under nonreducing conditions, thus indicating they are part of a
disulfide-linked dimer (not shown). The finding of a minor 43 kD band in
addition to the major 45 kD molecule raises the question of whether this molecule
may represent a differently glycosylated form of the 45 kD molecule, or rather
the molecular product of different gene(s).
Summary
Four clones were derived from human peripheral blood T lymphocytes from
which CD4+ and CD8+ cells had been removed by treatment with specific mAbs
and complement. All expressed the CD2+, 3+, 4-, 8-, T44- phenotype, and did
not react with the WT31 mAb, which is specific for a framework determinant
of the C133-associated a/ß heterodimer which serves as receptor for antigen on
most human T lymphocytes. Surface iodination followed by crosslinking with
dithiobis-succinimidyl propionate (DSP) and immunoprecipitation with anti-CD3
mAbs indicated that, in all four clones, the CD3-associated molecules consisted
of a major 45 kD band and a minor band of 43 kD. Northern blot analysis
showed that mRNA for the y chain was expressed at high levels, whereas mRNA
for the a chain was missing; ß chain mRNA was present in a defective form (I
kb instead of 1 .3 kb). These data support the concept that these clones may
express, in association with CD3, the molecular product of the T cell receptor 'y
genes instead of the typical a/ß heterodimer. CD3', WT31 - clones lysed the
NK-sensitive K562 target cells and produced IL-2 upon stimulation with PHA.
In addition, they released IL-2 after triggering with soluble anti-CD3 mAbs or
with an appropriate combination of anti-CD2 mAbs (in the presence of adherent
cells). When CD3', WT31 - clones were incubated with an anti-CD3 producing
hybridoma as triggering target, the latter was efficiently lysed. Target cell lysis
also occurred when a suitable combination of anti-CD2 mAbs-producing hybri-
domas was used. Therefore, CD3', WT31- cells appear to use two pathways of
cell activation that function also in conventional CD3', WT31' T cells, but they
lack a third putative pathway initiated by T44 surface molecules.
Receivedforpublication 3 March 1987 and in revised form 1 April 1987.
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